Abstract:

Objective　To observe the effect of Shenqi Fuzheng Liquid on improving cancer-induced fatigue, immune function, and adverse chemotherapy reactions in patients with lung cancer. Methods　This was a prospective study. A total of 123 patients with lung cancer who received treatment in Nanyang First People's Hospital from January 2021 to May 2022 were included as the study objects. The patients were divided into a control group (61 cases) and an observation group (62 cases) by the lottery method. There were 40 males and 21 females in the control group; they were (60.44±5.18) years old. There were 42 males and 20 females in the observation group; they were (60.27±5.35) years old. Both groups took routine chemotherapy; in addition, the observation group took Shenqi Fuzheng Liquid. The immune function before and after the treatment was compared between the two groups. The improvement of cancer-induced fatigue 7, 14, and 30 days after the treatment was observed. The occurrence of chemotherapy related adverse reactions and quality of life of the two groups were analyzed and compared through 6-month short-term follow-up. χ² and t tests were applied. Results　Before the treatment, there were no statistical differences in the immune function and score of Piper Fatigue Scale (PFS) between the two groups (all P>0.05). After the treatment, the CD3+ and CD4+ T lymphocyte subsets were higher and the CD8+ was lower in the observation group than in the control group [(70.35±10.46)% vs. (65.44±10.27) %, (40.22±8.47)% vs. (35.25±8.33)%, and (35.44±5.36)% vs. (38.25±5.46)%; all P<0.05]. The PFS scores 1,5, and 10 d after the treatment in the observation group were lower than those in the control group [(28.44±4.69) vs. (31.22±4.33), (23.39±5.37) vs. (26.44±5.82), and (20.27±2.28) vs. (23.47±4.15); all P<0.05]. During the follow-up period, the incidence of adverse chemotherapy reactions in the observation group was lower than that in the control group [9.68% (6/62) vs. 21.31% (13/61)]. The scores of Karnofsky Performance Status (KPS), quality of life (QOL), and Zubrod Performance Status (ZPS) in the observation group were better than those in the control group [(75.22±5.31) vs. (72.19±5.28), (48.44±5.23) vs. (45.15±5.19), and (2.12±0.75) vs. (3.32±1.26); all P<0.05]. Conclusion　Shenqi Fuzheng Liquid can effectively improve the immune function and cancer-induced fatigue level in patients with lung cancer chemotherapy, and has positive significance in reducing the risk of chemotherapy-related adverse reactions and improving the quality of life.

Key words:

Lung cancer, Shenqi Fuzheng Liquid, Cancer-related fatigue, Immune function, Chemotherapy-related adverse reactions, Quality of life

摘要：

目的　观察参芪扶正液对改善肺癌化疗患者癌因性疲乏、免疫功能及化疗不良反应的影响。方法　本文为前瞻性研究，纳入2021年1月至2022年5月于南阳市第一人民医院接受治疗的123例肺癌患者为研究对象，应用抽签法将患者分为对照组（61例）和观察组（62例）。对照组中男40例、女21例，年龄（60.44±5.18）岁；观察组中男42例、女20例，年龄（60.27±5.35）岁。对照组患者采用常规化疗，观察组在常规化疗基础上联合应用参芪扶正液治疗，比较两组患者治疗前后的免疫功能，治疗7、14、30 d后的癌因性疲乏改善情况。通过6个月短期随访统计并对比两组患者的化疗相关不良反应发生情况及生存质量。组间比较采用χ²检验、t检验。结果　治疗前，两组患者的免疫功能及Piper癌因性疲乏量表（PFS）评分差异均无统计学意义（均P>0.05）；治疗后，观察组的T淋巴细胞亚群CD3+为（70.35±10.46）%、CD4+为（40.22±8.47）%，均高于对照组［（65.44±10.27）%、（35.25±8.33）%］、CD8+为（35.44±5.36）%，低于对照组的（38.25±5.46）%（均P<0.05）。治疗1 d、5 d、10 d后，观察组的PFS评分分别为（28.44±4.69）分、（23.39±5.37）分、（20.27±2.28）分，均低于对照组［（31.22±4.33）分、（26.44±5.82）分、（23.47±4.15）分］（均P<0.05）。随访期间，观察组化疗相关不良反应发生率为9.68%（6/62），低于对照组的21.31%（13/61）；观察组功能状态评分（KPS）为（75.22±5.31）分、生活质量评分（QOL）为（48.44±5.23）分，均高于对照组［（72.19±5.28）分、（45.15±5.19）分］，体力状况评分（ZPS）为（2.12±0.75）分，低于对照组的（3.32±1.26）分（均P<0.05）。结论　参芪扶正液可有效改善肺癌化疗患者的免疫功能及癌因性疲乏水平，对降低化疗相关不良反应发生风险并提升生存质量均有积极意义。

关键词:

肺癌, 参芪扶正液, 癌因性疲乏, 免疫功能, 化疗相关不良反应, 生存质量